Rizatriptan Benzoate
Product Images NDC 50090-3921

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 50090-3921). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500903921)

The image shows a Rizatriptan Benzoate 10 mg bottle label from A-S Medication Solutions. The label includes NDC 50090-3921-0, lot number 6404-0, and states each tablet contains 10 mg of rizatriptan benzoate (5.70 mg rizatriptan equivalent). It indicates the bottle contains 18 unit dose tablets (3 x 6 blisters) and storage instructions to keep between 68 to 77 degrees Fahrenheit.*

FDA Label Image

Chemical Structure (Rizatriptan 01)

Chemical structure of rizatriptan benzoate, showing the molecular arrangements including the indole and pyrazole rings, methylated amine group, and benzoate moiety.*

FDA Label Image

Figure 1 (Rizatriptan 02)

A line graph showing the estimated probability of response over two hours post-dose for Rizatriptan benzoate tablets in 5 mg and 10 mg strengths compared to placebo. The graph plots response percentages on the y-axis against hours post-dose on the x-axis, depicting increasing response probabilities for both Rizatriptan benzoate doses versus placebo over time.*

FDA Label Image

Figure 2 (Rizatriptan 03)

A line chart showing the estimated probability of remediation or rescue over 24 hours post-dose. The graph compares placebo, Rizatriptan Benzoate tablets 5 mg, and Rizatriptan Benzoate tablets 10 mg, illustrating their effects over time.*

FDA Label Image

Figure 5 (Rizatriptan 04)

A line chart comparing the percent response with 95% confidence intervals over time (hours post stage 2 dose) between Rizatriptan Benzoate orally disintegrating tablets and placebo. The chart shows data points at 0.5, 1, 1.5, and 2 hours, with Rizatriptan demonstrating higher percent response at each time point compared to placebo.*

FDA Label Image

Image (Rizatriptan 05)

An instructional illustration showing hands pulling apart a blister unit from the blister pack by tearing along dotted lines (perforations). It visually guides how to separate a single dose unit for Rizatriptan Benzoate tablets from packaging.*

FDA Label Image

Image (Rizatriptan 06)

An instructional illustration showing hands peeling back lidding foil from a package. Below the image is the text instructing to peel the lidding foil from the 'PEEL HERE' portion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.